echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > China's second independent research and development of mRNA new crown vaccine products have been approved clinically

    China's second independent research and development of mRNA new crown vaccine products have been approved clinically

    • Last Update: 2021-01-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    On January 5, Tibet Pharmaceuticals announced that the mRNA new crown vaccine developed in cooperation with S microbiology Co., Ltd. (hereinafter referred to as "S microbiology") has been approved for clinical trials, which is the second self-developed mRNA new crown vaccine approved for clinical trials in China.
    in response to the outbreak of neo-crown pneumonia, the microbiome, in cooperation with the Chinese Center for Disease Control and Prevention and Tongji University-affiliated Oriental Hospital, launched an emergency mRNA new crown vaccine research and development project in January 2020.
    On June 16, 2020, Tibet Pharmaceuticals reached a cooperation agreement with Sri Microbiology to invest 351 million yuan in the development of the new crown vaccine, tuberculosis vaccine and influenza vaccine in a phased way to obtain the exclusive global authorization for the above-mentioned vaccine.
    , tibet's pharmaceutical industry has paid 35 million advance payments for microorganisms.
    also need to pay the corresponding milestone of 35 million yuan to the microorganisms after the approval of the clinic.
    In the future, if the Phase II clinical trial is completed, the corresponding milestone will be paid RMB60 million to S microbials, RMB 70 million in two payments, RMB 70 million in positive results in Phase III clinical trials registered with the Chinese drug regulator, and RMB150 million after being approved for listing by China's drug regulatory authorities.
    previously (June 19, 2020), the new coronavirus mRNA vaccine (ARCoV), developed by the Institute of Military Medicine of the Academy of Military Sciences in cooperation with local enterprises, became the first new coronary mRNA vaccine approved for clinical trials in China.
    source: Medical Copyright Notice: All text, images and audio and video materials that indicate "Source: Mets Medicine" or "Source: MedSci Originals" on this website are owned by Mets Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    at the same time reproduced content does not represent the position of this site.
    leave a message here
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.